glp 1 and gip glp 1 receptor agonists The dual glucose-dependent insulinotropic polypeptide (GIP) glucagon-like peptide-1 (GLP-1) agonist tirzepatide: a novel cardiometabolic therapeutic prospect | Cardiovascular Diabetology Possible mechanisms of action of
Description
The information provided reflects publicly available details from the company's website and general industry context
Psoriatic arthritis and metabolic syndrome: Is there a role for disease modifying anti-rheumatic drugs
Relationship between diet/exercise and pharmacotherapy to enhance the GLP1 levels in type 2 diabetes
From 2004 to 2009, an analysis of the database revealed a six-fold increase in pancreatitis incidents linked to the DPP-4 inhibitor sitagliptin and the GLP-1 mimetic exenatide, the first two GLP-1-based medications marketed in the US [51]
What is the safest medicine for kidneys
Sulphonylureas in the management of type 2 diabetes: to be or not to be
